Beneficial effect of coenzyme Q10 on increased oxidative and nitrative stress and inflammation and individual metabolic components developing in a rat model of metabolic syndrome

Journal of Pharmacological Sciences

Volumn 107, Issue 2, 2008, Pages 128-137

  Kunitomo, Masaru ^a   Yamaguchi, Yu ^a   Kagota, Satomi ^a   Otsubo, Kazumasa ^b  

^a MUKOGAWA WOMEN'S UNIVERSITY   (Japan)

^b ASAHI KASEI PHARMA CORPORATION   (Japan)

Author keywords

Coenzyme Q10; Endothelial dysfunction; Inflammation; Metabolic syndrome model rat; Oxidative stress

Indexed keywords

3 CHLOROTYROSINE; 3 NITROTYROSINE; 8 HYDROXYDEOXYGUANOSINE; C REACTIVE PROTEIN; INSULIN; MYELOPEROXIDASE; OXIDIZED LOW DENSITY LIPOPROTEIN; UBIDECARENONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CATALYSIS; CONTROLLED STUDY; DIET SUPPLEMENTATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG EFFECT; DYSLIPIDEMIA; ENDOTHELIAL DYSFUNCTION; GLUCOSE BLOOD LEVEL; HYPERTENSION; INFLAMMATION; MALE; METABOLIC SYNDROME X; NITRATIVE STRESS; NONHUMAN; OXIDATION; OXIDATIVE STRESS; RAT; WEIGHT GAIN;

EID: 46449129625     PISSN: 13478613     EISSN: 13478648     Source Type: Journal    
DOI: 10.1254/jphs.FP0072365     Document Type: Article

References (51)

1. Grundy SM, Cleeman JI, Daniels SR, Donato KA, Eckel RH, Franklin BA, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112:2735-2752.
2. Reaven GM. Metabolic syndrome: pathophysiology and implications for management of cardiovascular disease. Circulation. 2002;206:286-288.
3. Cheal KL, Abbasi F, Lamendola C, McLaughlin T, Reaven GM, Ford ES. Relationship to insulin resistance of the adult treatment panel III diagnostic criteria for identification of the metabolic syndrome. Diabetes. 2004;53:1195-1200.
4. Dandona P, Aljada A, Chaudhuri A, Mohanty P, Garg R. Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation. Circulation. 2005;111:1448-1454.
5. Shoelson SE, Herrero L, Naaz A. Obesity, inflammation, and insulin resistance. Gastroenterology. 2007;132:2169-2180.
6. Fujita K, Nishizawa H, Funahashi T, Shimomura I, Shimabukuro M. Systemic oxidative stress is associated with visceral fat accumulation and the metabolic syndrome. Circ J. 2006;70:1437-1442.
7. Sigurdardottir V, Fagerberg B, Hulthe J. Circulating oxidized low-density lipoprotein (LDL) is associated with risk factors of the metabolic syndrome and LDL size in clinically healthy 58-year-old men (AIR study). J Intern Med. 2002;252:440-447.
8. Lapointe A, Couillard C, Piche ME, Weisnagel SJ, Bergeron J, Nadeau A, et al. Circulating oxidized LDL is associated with parameters of the metabolic syndrome in postmenopausal women. Atherosclerosis. 2007;191:362-368.
9. Crane FL, Hatefi Y, Lester RL, Widmer C. Isolation of a quinone from beef heart mitochondria. Biochim Biophys Acta. 1957;25:220-221.
10. Frei B, Kim MC, Ames BN. Ubiquinol-10 is an effective lipid-soluble antioxidant at physiological concentrations. Proc Natl Acad Sci U S A. 1990;87:4879-4883.
11. Ernster L, Dallner G. Biochemical, physiological and medical aspects of ubiquinone function. Biochim Biophys Acta. 1995;1271:195-204.
12. Rosenfeldt FL, Haas SJ, Krum H, Hadj A, Ng K, Leong JY, et al. Coenzyme Q10 in the treatment of hypertension: a meta-analysis of the clinical trials. J Hum Hypertens. 2007;21:297-306.
13. Pepe S, Marasco SF, Haas SJ, Sheeran FL, Krum H, Rosenfeldt FL. Coenzyme Q10 in cardiovascular disease. Mitochondrion. 2007;7 Suppl:S154-S167.
14. Singh U, Devaraj S, Jialal I. Coenzyme Q10 supplementation and heart failure. Nutr Rev. 2007;65:286-293.
15. Miles MV, Morrison JA, Horn PS, Tang PH, Pesce AJ. Coenzyme Q10 changes are associated with metabolic syndrome. Clin Chim Acta. 2004;344:173-179.
16. Nagase M, Yoshida S, Shibata S, Nagase T, Gotoda T, Ando K, et al. Enhanced aldosterone signaling in the early nephropathy of rats with metabolic syndrome: possible contribution of fat-derived factors. J Am Soc Nephrol. 2006;17:3438-3446.
17. Velliquette RA, Kossover R, Previs SF, Ernsberger P. Lipid-lowering actions of imidazoline antihypertensive agents in metabolic syndrome X. Naunyn Schmiedebergs Arch Pharmacol. 2006;372:300-312.
18. Kagota S, Yamaguchi Y, Tanaka N, Kubota Y, Kobayashi K, Nejime N, et al. Disturbances in nitric oxide/cyclic guanosine monophosphate system in SHR/NDmcr-cp rats, a model of metabolic syndrome. Life Sci. 2006;78:1187-1196.
19. Yamaguchi Y, Yoshikawa N, Kagota S, Nakamura K, Haginaka J, Kunitomo M. Elevated circulating levels of markers of oxidative-nitrative stress and inflammation in a genetic rat model of metabolic syndrome. Nitric Oxide. 2006;15:380-386.
20. Yamashita S, Yamamoto Y. Simultaneous detection of ubiquinol and ubiquinone in human plasma as a marker of oxidative stress. Anal Biochem. 1997;250:66-73.
21. Yamaguchi Y, Kagota S, Kunitomo M, Haginaka J. Evidence of modified lipoprotein in the plasma of Watanabe Heritable Hyperlipidaemic rabbits by anion-exchange high-performance liquid chromatographic assay. Atherosclerosis. 1998;139:323-331.
22. Yamaguchi Y, Kagota S, Haginaka J, Kunitomo M. Participation of peroxynitrite in oxidative modification of LDL by aqueous extracts of cigarette smoke. FEBS Lett. 2002;512:218-222.
23. Long L, Mccabe DR, Dolan ME. Determination of 8-oxoguanine in human plasma and urine by high-performance liquid chromatography with electrochemical detection. J Chromatgr B. 1999;731:241-249.
24. Kunitomo M, Yamaguchi Y, Matsushima K, Bando Y. Cholesterol metabolism in serum and aorta of inbred mice fed a high-cholesterol diet. Jpn J Pharmacol. 1984;34:153-158.
25. Yamaguchi Y, Kunitomo M, Haginaka J. Anion-exchange high-performance liquid chromatographic assay of plasma lipoproteins of rabbits, rats and mice. J Chromatogr B Biomed Sci Appl. 1998;716:57-64.
26. Witztum JL. The oxidation hypothesis of atherosclerosis. Lancet. 1994;344:793-795.
27. Harrison D, Griendling KK, Landmesser U, Hornig B, Drexler H. Role of oxidative stress in atherosclerosis. Am J Cardiol. 2003;91:7A-11A.
28. Madamanchi NR, Vendrov A, Runge MS. Oxidative stress and vascular disease. Arterioscler Thromb Vasc Biol. 2005;25:29-38.
29. Nyby MD, Abedi K, Smutko V, Eslami P, Tuck ML. Vascular angiotensin type 1 receptor expression is associated with vascular dysfunction, oxidative stress and inflammation in fructose-fed rats. Hypertens Res. 2007;30:451-457.
30. Kaliora AC, Dedoussis GV, Schmidt H. Dietary antioxidants in preventing atherogenesis. Atherosclerosis. 2006;187:1-17.
31. Kwong LK, Kamzalov S, Rebrin I, Bayne AC, Jana CK, Morris P, et al. Effects of coenzyme Q(10) administration on its tissue concentrations, mitochondrial oxidant generation, and oxidative stress in the rat. Free Radic Biol Med. 2002;33:627-638.
32. Witztum JL, Steinberg D. Role of oxidized low density lipoprotein in atherogenesis. J Clin Invest. 1991;88:1785-1792.
33. Hulthe J, Fagerberg B. Circulating oxidized LDL is associated with subclinical atherosclerosis development and inflammatory cytokines (AIR Study). Arterioscler Thromb Vasc Biol. 2002;22:1162-1167.
34. Floyd RA, West MS, Eneff KL, Schneider JE, Wong PK, Tingey DT, et al. Conditions influencing yield and analysis of 8-hydroxy-2′-deoxyguanosine in oxidatively damaged DNA. Anal Biochem. 1990;188:155-158.
35. Somfai GM, Knippel B, Ruzicska E, Stadler K, Toth M, Salacz G, et al. Soluble semicarbazide-sensitive amine oxidase (SSAO) activity is related to oxidative stress and subchronic inflammation in streptozotocin-induced diabetic rats. Neurochem Int. 2006;48:746-752.
36. Libby P, Ridker PM. Novel inflammatory markers of coronary risk: theory versus practice. Circulaton. 1999;100:1148-1150.
37. Himmelfarb J, McMenamin E, Loseto G, Heinecke JW. Myeloperoxidase- catalyzed 3-chlorotyrosine formation in dialysis patients. Free Radic Biol Med. 2001;31:1163-1169.
38. Gaut JP, Byun J, Tran HD, Lauber WM, Carroll JA, Hotchkiss RS, et al. Myeloperoxidase produces nitrating oxidants in vivo. J Clin Invest. 2002;109:1311-1319.
39. Shigenaga MK, Lee HH, Blount BC, Christen S, Shigeno ET, Yip H, et al. Inflammation and NOx-induced nitration: assay for 3-nitrotyrosine by HPLC with electrochemical detection. Proc Natl Acad Sci U S A. 1997;94:3211-3216.
40. Moghadasian MH. Experimental atherosclerosis: a historical overview. Life Sci. 2002;70:855-865.
41. Bartus M, Lomnicka M, Lorkowska B, Franczyk M, Kostogrys RB, Pisulewski PM, et al. Hypertriglyceridemia but not hypercholesterolemia induces endothelial dysfunction in the rat. Pharmacol Rep. 2005;57 Suppl:127-137.
42. Chapman MJ. Metabolic syndrome and type 2 diabetes: lipid and physiological consequences. Diab Vasc Dis Res. 2007;4 Suppl 3:S5-S8.
43. Cai H, Harrison DG. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res. 2000;87:840-844.
44. Kagota S, Tada Y, Kubota Y, Nejime N, Yamaguchi Y, Nakamura K, et al. Peroxynitrite is involved in the dysfunction of vasorelaxation in SHR/NDmcr-cp rats, spontaneously hypertensive obese rats. J Cardiovas Pharmacol. 2007;50:677-685.
45. Ferroni P, Basili S, Paoletti V, Davi G. Endothelial dysfunction and oxidative stress in arterial hypertension. Nutr Metab Cardiovasc Dis. 2006;16:222-233.
46. Taddei S, Virdis A, Mattei P, Salvetti A. Vasodilation to acetylcholine in primary and secondary forms of human hypertension. Hypertension. 1993;21:929-933.
47. Steinberg HO, Chaker H, Leaming R, Johnson A, Brechtel G, Baron AD. Obesity/insulin resistance is associated with endothelial dysfunction: implications for the syndrome of insulin resistance. J Clin Invest. 1996;97:2601-2610.
48. Arcaro G, Cretti A, Balzano S, Lechi A, Muggeo M, Bonora E, et al. Insulin causes endothelial dysfunction in humans: sites and mechanisms. Circulation. 2002;105:576-582.
49. Picchi A, Gao X, Belmadani S, Potter BJ, Focardi M, Chilian WM, et al. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome. Circ Res. 2006;99:69-77.
50. Ginsberg HN. Insulin resistance and cardiovascular disease. J Clin Invest. 2000;106:629-631.
51. Ceriello A, Motz E. Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol. 2004;24:816-823.